Memo Therapeutics AG (MTx), a pioneering late-stage biotech firm based in Schlieren, Zurich, has successfully secured a notable financing round, raising a remarkable $20 million. The funding is intended to propel MTx's innovative approach of transforming unique human immune responses into advanced therapies, particularly in the realms of viral infections and cancer. Central to this funding initiative is the development of the Company’s lead program, Potravitug, which is currently in Phase II clinical trials aimed at combating BK viremia (BKV) in kidney transplant recipients. BKV can severely affect kidney functionality and patient survival, making Potravitug a potential first-in-class therapy that could significantly improve outcomes in this underserved patient population.
In addition to Potravitug, MTx is on the forefront of novel cancer therapies, leveraging its proprietary DROPZYLLA® technology, which excels in high-throughput antibody repertoire screening. This technology enables MTx to discover promising antibody-target pairs, specifically focusing on therapeutic strategies for oncology. The Company has also formed strategic partnerships, notably with Ono Pharmaceutical, to further advance its oncology targets. The recent infusion of capital from esteemed investors, including Ysios Capital, Kurma Partners, and Swisscanto, underscores the confidence in MTx's potential to deliver transformative treatments that can enhance patient survival and quality of life. As MTx continues to innovate within the biotechnology landscape, this funding marks a significant step forward in its mission to develop best-in-class medicines that harness the power of the human immune system.
